Zanaflex Capsule
Product Images NDC 73352-090

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 73352-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Trifluent Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Zanaflex Label V1)

Zanaflex 8 mg capsules label showing the active ingredient tizanidine hydrochloride equivalent to 8 mg tizanidine base. The label includes storage instructions, a warning to keep out of reach of children, and a note that the capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. Distributed by Trifluent Pharma, LLC, the package contains 60 capsules with Rx only status. Barcode and trademark information are visible.*

FDA Label Image

Image Description (Zan01 0001 01a)

Chemical structure of tizanidine hydrochloride, the active ingredient in Zanaflex 8 mg capsules. The diagram depicts the molecular arrangement including a chlorinated benzene ring, imidazoline group, and hydrochloride ion.*

FDA Label Image

Image Description (Zan01 0001 02a)

A line chart depicting the plasma concentration of tizanidine in ng/mL over 24 hours after dosing. The graph compares four conditions: 2 x 4 mg tizanidine tablets with food, without food, and 2 x 4 mg tizanidine capsules with food, without food. The x-axis represents hours from dosing, and the y-axis shows plasma tizanidine concentration. Lines illustrate changes in concentration for each condition over time.*

FDA Label Image

Image Description (Zan01 0001 03a)

A line graph depicting improvement in Ashworth Score over time in hours post-dose, comparing three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis shows improvement levels, with error bars indicating variability, while the horizontal axis represents hours from 0 to 6 post-dose.*

FDA Label Image

Image Description (Zan01 0001 04a)

A line graph comparing improvement in Ashworth Score over time between tizanidine (mean dose 28.8 mg) and placebo groups. The x-axis shows study time points: End of Titration (Week 3), End of Maintenance, and Endpoint (Last Observation). The y-axis indicates improvement scores, with tizanidine showing greater improvement than placebo at all points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.